AN2 Therapeutics, Inc.
ANTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001880438
In the last 90 days, AN2 Therapeutics, Inc. insiders filed 1 open-market purchase and 5 sales; 66 institutions reported holding it in 13F filings for Q2 2026, worth $119.0M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by AN2 Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $11.6K in total
- Open-market sells
- 5 filings
- 3 insiders, $343.0K in total
- Insiders trading
- 4
- Net value
- −$331.4K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for AN2 Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Trenor Cameron C. III | Chief Medical Officer | 116,667 | Sep 16, 2026 | 1 |
| Readnour Robin Shane | Director | 624,765Indirect | Sep 11, 2026 | 5 |
| Williams Sarah Joanne | Principal Accounting Officer | 66,311 | Sep 4, 2026 | 4 |
| FitzPatrick Margaret M | Director | 10,708 | Sep 2, 2026 | 3 |
| Zakrzewski Joseph S | Director | 0Indirect | Aug 14, 2026 | 3 |
| Aziz Kabeer | Director | 59,106 | Jul 10, 2026 | 6 |
| Marks Gilbert Lynn | Director | 81,873 | Jul 10, 2026 | 6 |
| Martin Patricia A. | Director | 18,863 | Jul 10, 2026 | 6 |
| Eizen Joshua M | See Remarks | 206,554 | Jul 10, 2026 | 5 |
| Spigelman Melvin K | Director | – | Mar 23, 2026 | 2 |
| Wong Stephanie | Director | – | Mar 23, 2026 | 2 |
| Chanda Sanjay | Chief Development Officer | 118,823 | Mar 23, 2026 | 3 |
| Easom Eric | Chief Executive Officer | 368,630 | Mar 23, 2026 | 2 |
| Day Lucy | Chief Financial Officer | 118,363 | Mar 23, 2026 | 3 |
| Prior Stephen David | Chief Strategy Officer | 59,086 | Jan 7, 2026 | 2 |
| Leonard Braden Michael | 10% Owner | 3,017,432Indirect | Jun 16, 2025 | 0 |
| RA Capital Healthcare Fund LP | 10% Owner | 300,853Indirect | Aug 13, 2024 | 0 |
| Ra Capital Management, L.P. | 10% Owner | 300,853Indirect | Aug 13, 2024 | 0 |
| Kolchinsky Peter | 10% Owner | 300,853Indirect | Aug 13, 2024 | 0 |
| Shah Rajeev M. | 10% Owner | 300,853Indirect | Aug 13, 2024 | 0 |
| RA Capital Nexus Fund II, L.P. | 10% Owner | 300,853Indirect | Aug 13, 2024 | 0 |
| Eckburg Paul | Chief Medical Officer | 51,416 | Mar 29, 2024 | 0 |
| Krause Kevin Michael | Chief Strategy Officer | 31,914 | Mar 29, 2024 | 0 |
| Adjuvant Global Health Technology Fund, L.P. | 10% Owner | 377,542Indirect | Jan 18, 2024 | 0 |
| Adjuvant Global Health Technology Fund DE, L.P. | 10% Owner | 377,542Indirect | Jan 18, 2024 | 0 |
| Adjuvant Capital Management, LLC | 10% Owner | 377,542Indirect | Jan 18, 2024 | 0 |
| Adjuvant Capital GP, L.P. | 10% Owner | 377,542Indirect | Jan 18, 2024 | 0 |
| Nazak Michael Adrian | Chief Accounting Officer | – | Feb 17, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 2023 (view filing) | Sep 13 | 2 days | Aziz KabeerDirector, 10% Owner | SSale | −400 | $16.00 | −$6.40K | −0.1%411.9K after | 2 lots |
| Sep 8, 2023 (view filing)4:59 PM ET | Sep 6-7 | 2 days | Adjuvant Global Health Technology Fund, L.P. and 3 others10% Owner | SSale | −6.00K | $16.03 | −$96.3K | −0.3%2.18M after | 2 lots |
| Sep 8, 2023 (view filing)4:59 PM ET | Sep 6-7 | 2 days | Adjuvant Global Health Technology Fund, L.P. and 3 others10% Owner | SSale | −1.14K | $16.03 | −$18.2K | −0.3%412.0K after | 2 lots |
| Sep 8, 2023 (view filing) | Sep 6-7 | 2 days | Aziz KabeerDirector, 10% Owner | SSale | −7.14K | $16.03 | −$114.5K | −1.7%412.0K after | 4 lots |
| Aug 25, 2023 (view filing)4:31 PM ET | Aug 23 | 2 days | Adjuvant Global Health Technology Fund, L.P. and 3 others10% Owner | SSale | −336 | $16.00 | −$5.38K | 0.0%2.18M after | |
| Aug 25, 2023 (view filing)4:31 PM ET | Aug 23 | 2 days | Adjuvant Global Health Technology Fund, L.P. and 3 others10% Owner | SSale | −64 | $16.00 | −$1.02K | 0.0%413.1K after | |
| Aug 25, 2023 (view filing) | Aug 23 | 2 days | Aziz KabeerDirector, 10% Owner | SSale | −400 | $16.00 | −$6.40K | −0.1%413.1K after | 2 lots |
| Aug 22, 2023 (view filing)5:01 PM ET | Aug 18 | 4 days | RA Capital Healthcare Fund LP and 4 others10% Owner | PPurchase | +1.78M | $9.00 | +$16.0M | +52.9%5.14M after | |
| May 15, 2023 (view filing) | May 15 | Same day | Easom EricChief Executive Officer | PPurchase | +10.0K | $5.38 | +$53.8K | +1.0%1.02M after | |
| Nov 14, 2022 (view filing) | Nov 10-14 | 4 days | Easom EricChief Executive Officer | SSale | −4.44K | $15.32 | −$68.0K | −47.5%4.91K after | 2 lots |
| Nov 9, 2022 (view filing) | Nov 8-9 | 1 day | Easom EricChief Executive Officer | SSale | −17.2K | $15.60 | −$267.8K | −77.8%4.91K after | 3 lots |
| Nov 7, 2022 (view filing) | Nov 3-7 | 4 days | Easom EricChief Executive Officer | SSale | −35.2K | $15.86 | −$558.2K | −87.8%4.91K after | 5 lots |
| Nov 2, 2022 (view filing) | Oct 31-Nov 2 | 2 days | Easom EricChief Executive Officer | SSale | −4.23K | $15.27 | −$64.6K | −46.3%4.91K after | 2 lots |
| Oct 28, 2022 (view filing) | Oct 27-28 | 1 day | Easom EricChief Executive Officer | SSale | −2.61K | $15.19 | −$39.6K | −34.7%4.91K after | 2 lots |
| Oct 26, 2022 (view filing) | Oct 24-26 | 2 days | Easom EricChief Executive Officer | SSale | −9.35K | $15.76 | −$147.4K | −65.6%4.91K after | 4 lots |
| Oct 24, 2022 (view filing) | Oct 20-21 | 4 days | Easom EricChief Executive Officer | SSale | −21.2K | $16.47 | −$349.9K | −81.2%4.91K after | 4 lots |
| Aug 5, 2022 (view filing)4:06 PM ET | Aug 3-4 | 2 days | RA Capital Healthcare Fund LP and 4 others10% Owner | PPurchase | +1.91K | $7.51 | +$14.3K | +0.1%3.77M after | 2 lots |
| Jul 28, 2022 (view filing)5:16 PM ET | Jul 26-27 | 2 days | RA Capital Healthcare Fund LP and 4 others10% Owner | PPurchase | +23.2K | $7.78 | +$180.7K | +0.6%3.77M after | 2 lots |
| Jun 24, 2022 (view filing)4:51 PM ET | Mar 29 | 87 days | Adjuvant Global Health Technology Fund, L.P. and 3 others10% Owner | PPurchase | +166.7K | $15.00 | +$2.50M | +8.2%2.21M after | AmendedDuplicate filing |
| Jun 23, 2022 (view filing)4:31 PM ET | Jun 21 | 2 days | RA Capital Healthcare Fund LP and 4 others10% Owner | PPurchase | +302 | $7.99 | +$2.41K | 0.0%3.75M after | |
| Jun 15, 2022 (view filing)4:25 PM ET | Jun 13-14 | 2 days | RA Capital Healthcare Fund LP and 4 others10% Owner | PPurchase | +81.4K | $7.95 | +$647.4K | +2.2%3.75M after | 2 lots |
| Mar 31, 2022 (view filing)8:15 PM ET | Mar 29 | 2 days | Adjuvant Global Health Technology Fund, L.P. and 1 other10% Owner | PPurchase | +166.7K | $15.00 | +$2.50M | +8.2%2.21M after | Duplicate filing |
| Mar 31, 2022 (view filing)4:31 PM ET | Mar 29 | 2 days | RA Capital Healthcare Fund LP and 4 others10% Owner | PPurchase | +1.67M | $15.00 | +$25.0M | New position415.6K after | 2 lots |
| Mar 31, 2022 (view filing) | Mar 29 | 2 days | Readnour Robin ShaneDirector | PPurchase | +153.3K | $15.00 | +$2.30M | +45.9%487.6K after | 2 lots |
| Mar 31, 2022 (view filing) | Mar 29 | 2 days | Aziz KabeerDirector, 10% Owner | PPurchase | +166.7K | $15.00 | +$2.50M | +8.2%2.21M after |